-
EP2459195
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2459195
| EP2459195 - COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 01.11.2019 Database last updated on 11.04.2026 | |
| Former | Examination is in progress Status updated on 15.02.2017 | Most recent event Tooltip | 01.11.2019 | Application deemed to be withdrawn | published on 04.12.2019 [2019/49] | Applicant(s) | For all designated states Rigel Pharmaceuticals, Inc. 1180 Veterans Boulevard South San Francisco, CA 94080 / US | [2012/23] | Inventor(s) | 01 /
TAYLOR, Vanessa 2087 Golden Gate Avenue San Francisco CA 94115 / US | 02 /
LI, Hui 2576 Amethyst Drive Santa Clara CA 95051 / US | 03 /
SINGH, Rajinder 1832 Hillman Avenue Belmont CA 94002 / US | [2012/23] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [N/P] |
| Former [2012/23] | Sexton, Jane Helen J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | Application number, filing date | 10738139.4 | 28.07.2010 | WO2010US43592 | Priority number, date | US20090229191P | 28.07.2009 Original published format: US 229191 P | [2012/23] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2011017178 | Date: | 10.02.2011 | Language: | EN | [2011/06] | Type: | A1 Application with search report | No.: | EP2459195 | Date: | 06.06.2012 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.02.2011 takes the place of the publication of the European patent application. | [2012/23] | Search report(s) | International search report - published on: | EP | 10.02.2011 | Classification | IPC: | A61K31/505, A61P27/02, A61P27/06, A61P27/14 | [2012/23] | CPC: |
A61K31/505 (EP,CN,KR,US);
A61K45/06 (EP,US);
A61K9/0048 (EP,KR,US);
A61K9/06 (EP,KR,US);
A61K9/08 (EP,KR,US);
A61K9/10 (KR);
A61P27/02 (EP);
A61P27/04 (EP);
A61P27/06 (EP);
| C-Set: |
A61K31/505, A61K2300/00 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/23] | Title | German: | ZUSAMMENSETZUNGEN UND VERFAHREN ZUR HEMMUNG DES JAK-SIGNALWEGES | [2012/23] | English: | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | [2012/23] | French: | COMPOSITIONS ET PROCÉDÉS POUR L INHIBITION DE LA VOIE JAK | [2012/23] | Entry into regional phase | 01.02.2012 | National basic fee paid | 01.02.2012 | Designation fee(s) paid | 01.02.2012 | Examination fee paid | Examination procedure | 01.02.2012 | Examination requested [2012/23] | 14.09.2012 | Amendment by applicant (claims and/or description) | 19.12.2014 | Despatch of a communication from the examining division (Time limit: M04) | 29.04.2015 | Reply to a communication from the examining division | 19.10.2016 | Despatch of a communication from the examining division (Time limit: M06) | 08.08.2017 | Reply to a communication from the examining division | 19.12.2018 | Despatch of a communication from the examining division (Time limit: M06) | 02.07.2019 | Application deemed to be withdrawn, date of legal effect [2019/49] | 24.07.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2019/49] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 19.12.2014 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 08.08.2017 | Request for further processing filed | 08.08.2017 | Full payment received (date of receipt of payment) Request granted | 22.08.2017 | Decision despatched | Fees paid | Renewal fee | 25.07.2012 | Renewal fee patent year 03 | 29.07.2013 | Renewal fee patent year 04 | 28.07.2014 | Renewal fee patent year 05 | 27.07.2015 | Renewal fee patent year 06 | 27.07.2016 | Renewal fee patent year 07 | 27.07.2017 | Renewal fee patent year 08 | 27.07.2018 | Renewal fee patent year 09 | 29.07.2019 | Renewal fee patent year 10 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X] US2007203161 (ARGADE ANKUSH et al.) [X] 1-3,8-12 * page 14; table I; compounds I-6, I-8 * * paragraphs [0141] , [0187] , [ 188] , [ 199] , [ 205] , [ 258] , [ 281] , [ 297] - [0304] - [ 381] - [0384] * * claim 6; compounds I-6, I-8 * | [X] WO2009003136 (RIGEL PHARMACEUTICALS INC et al.) [X] 1-3,8-12 * paragraphs [0027] , [0 41] , [ 315] , [ 324] , [ 334] , [ 362] , [ 379] * * page 88; table 3; compound 10 * | [A] WO2009007839 (PFIZER et al.) [A] 1-3,8-12 * the whole document * | [A] WO2007107318 (NOVARTIS AG et al.) [A] 1-3,8-12 * page 11, line 3 - page 16, line 17 * | [A] WO2004026406 (ALCON INC et al.) [A] 1-3,8-12 * page 4, lines 25-28 * | Examination | SHIAO HUI (MELISSA) LIEW ET AL: "Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US, vol. 119, no. 7, 13 January 2012 (2012-01-13), pages 1328 - 1335, XP028504561, ISSN: 0161-6420, [retrieved on 20120118], DOI: 10.1016/J.OPHTHA.2012.01.028 [T] DOI: http://dx.doi.org/10.1016/j.ophtha.2012.01.028 | by applicant | US4256108 | US4166452 | US4265874 | US6261547 | US6197934 | US6056950 | US5800807 | US5776445 | US5698219 | US5521222 | US5403841 | US5077033 | US4882150 | US4738851 | US2004029902 | WO03063794 | US63102903 | WO2004014382 | US90326304 | WO2005016893 | US7491732 | US2007203161 | CLIN EXP IMMUNOL., vol. 109, 1997, pages 555 - 561 | CLIN IMMUNOL., vol. 103, 2002, pages 111 - 124 |